{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:39Z","timestamp":1791219459928,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We evaluated the performance of two scoring systems\u2014the Bladder Cancer Italian Active Surveillance (BIAS) criteria and the International Bladder Cancer Group (IBCG) score\u2014for predicting high-grade (HG) disease at recurrence in patients with primary low-grade (LG) non-muscle-invasive bladder cancer eligible for active surveillance (AS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively included patients with primary LG-NMIBC (2013\u20132022), eligible for AS according to BIAS criteria at time of diagnosis. All subsequent recurrences were managed with TURBT, allowing histopathological confirmation of tumor grade across 383 recurrences. Clinical data necessary to assess IBCG criteria and adherence to BIAS protocol were systematically collected at each recurrence, and their diagnostic performance in predicting HG progression was evaluated using C-statistics. Multivariable logistic regression was used to assess which individual BIAS and IBCG criteria were most predictive of progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At a median (IQR) follow-up of 55 (18\u201383) months, HG progression occurred in 45\/383 (12%) of recurrences. BIAS criteria were met in 59% (226\/383) of recurrences, of which 5.3% showed upgrading to HG. Conversely, only 16% (62\/383) of recurrences had 0 IBCG risk factors, of which 8 (13%) upgraded. BIAS showed higher discriminative ability than IBCG (C-statistics 0.68 vs. 0.47,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) and higher negative predictive value (95% vs. 87%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with primary LG-NMIBC initially eligible for AS, adherence to BIAS criteria at recurrence identifies a subgroup with a lower prevalence of HG disease at immediate TURBT and may help inform shared decision-making regarding surveillance versus immediate intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05411-x","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:16:34Z","timestamp":1791216994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation of BIAS and IBCG criteria for predicting high-grade recurrence in low-grade NMIBC eligible for active surveillance"],"prefix":"10.1007","author":[{"given":"Marco","family":"Finati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ricapito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"d\u2019Altilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Giannoccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savio Domenico","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Naspro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roscigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Filippo","family":"Da Pozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Bettocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"5411_CR1","unstructured":"Gontero P, et al (2026) EAU Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). 2026 ed. Presented at the 41st EAU Annual Congress, London, 2026. EAU Guidelines Office, Arnhem, The Netherlands. Available at: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer. Accessed May 22, 2026"},{"key":"5411_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.euo.2025.04.010","volume":"8","author":"R Contieri","year":"2025","unstructured":"Contieri R et al (2025) Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer. Eur Urol Oncol 8:977\u2013985","journal-title":"Eur Urol Oncol"},{"key":"5411_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euf.2023.06.012","volume":"10","author":"J Ma","year":"2024","unstructured":"Ma J et al (2024) Long-term recurrence rates of low-risk non-muscle-invasive bladder cancer-How long is cystoscopic surveillance necessary? Eur Urol Focus 10:189\u2013196","journal-title":"Eur Urol Focus"},{"key":"5411_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","volume":"8","author":"R Contieri","year":"2025","unstructured":"Contieri R et al (2025) Deintensification of treatment for low-grade bladder tumors: a collaborative review by the International Bladder Cancer Group (IBCG). Eur Urol Oncol 8:179\u2013189","journal-title":"Eur Urol Oncol"},{"key":"5411_CR5","doi-asserted-by":"publisher","unstructured":"Contieri R, et al (2026) Active surveillance in low-grade NMIBC\u2014results of an international two-round modified Delphi consensus. Nat Rev Urol https:\/\/doi.org\/10.1038\/s41585-026-01137-8","DOI":"10.1038\/s41585-026-01137-8"},{"key":"5411_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","volume":"170","author":"MS Soloway","year":"2003","unstructured":"Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170:438\u2013441","journal-title":"J Urol"},{"key":"5411_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","volume":"87","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P et al (2025) The financial burden of localized and metastatic bladder cancer. Eur Urol 87:536\u2013550","journal-title":"Eur Urol"},{"key":"5411_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan WS et al (2022) Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group. Eur Urol Oncol 5:505\u2013516","journal-title":"Eur Urol Oncol"},{"key":"5411_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.euo.2025.08.003","volume":"8","author":"R Li","year":"2025","unstructured":"Li R et al (2025) Intermediate-risk non-muscle-invasive bladder cancer: recommendations for definitions, risk stratification, management strategies, and clinical trial design from the International Bladder Cancer Group. Eur Urol Oncol 8:1685\u20131695","journal-title":"Eur Urol Oncol"},{"key":"5411_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","volume":"7","author":"F Soria","year":"2024","unstructured":"Soria F et al (2024) Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter Young Academic Urologists Urothelial Working Group collaboration. Eur Urol Oncol 7:1497\u20131503","journal-title":"Eur Urol Oncol"},{"key":"5411_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","volume":"5","author":"R Contieri","year":"2022","unstructured":"Contieri R et al (2022) Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience. Eur Urol Oncol 5:251\u2013255","journal-title":"Eur Urol Oncol"},{"key":"5411_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bju.13536","volume":"118","author":"R Hurle","year":"2016","unstructured":"Hurle R et al (2016) Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder Cancer Italian Active Surveillance (BIAS) project. BJU Int 118:935\u2013939","journal-title":"BJU Int"},{"key":"5411_CR13","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Urinary and male genital tumours. International Agency for Research on Cancer 5th Edn.; 8. 2022. https:\/\/publications.iarc.fr\/610"},{"key":"5411_CR14","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1161\/CIR.0000000000001401","volume":"153","author":"SS Khan","year":"2026","unstructured":"Khan SS et al (2026) Criteria to assess the predictive and clinical utility of novel models, biomarkers, and tools for risk of cardiovascular disease: a scientific statement from the American Heart Association. Circulation 153:e953\u2013e970","journal-title":"Circulation"},{"key":"5411_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/JU.0000000000003639","volume":"210","author":"WS Tan","year":"2023","unstructured":"Tan WS et al (2023) International Bladder Cancer Group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance. J Urol 210:763\u2013770","journal-title":"J Urol"},{"key":"5411_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.euros.2025.10.017","volume":"82","author":"M Finati","year":"2025","unstructured":"Finati M et al (2025) Refining active surveillance eligibility in intermediate-risk non-muscle-invasive bladder cancer: the impact of time to first recurrence. Eur Urol Open Sci 82:155\u2013159","journal-title":"Eur Urol Open Sci"},{"key":"5411_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00345-024-05417-z","volume":"43","author":"P Zaurito","year":"2024","unstructured":"Zaurito P et al (2024) Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer. World J Urol 43:52","journal-title":"World J Urol"},{"key":"5411_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.euo.2024.09.011","volume":"8","author":"F Liedberg","year":"2025","unstructured":"Liedberg F, Mariappan P, Gontero P (2025) Clinical implementation of urinary biomarkers for surveillance of non\u2013muscle-invasive bladder cancer (NMIBC): considerations from the European Association of Urology NMIBC Guideline Panel. Eur Urol Oncol 8:234\u2013236","journal-title":"Eur Urol Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05411-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05411-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:16:36Z","timestamp":1791216996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05411-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":18,"alternative-id":["5411"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05411-x","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethical Committee of Policlinico Riuniti of Foggia on March 15, 2022 (Approval Code 31\/CE\/2022).","order":1,"name":"Ethics","label":"Approval of the research protocol by an Institutional Reviewer Board","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any relevant disclosures, and none of the authors have any financial or non-financial interests that may be relevant to the submitted work.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An institutional waiver of informed consent was granted due to the retrospective nature of the registry.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}